Key Takeaways; Cannabis Sector

• Tilray Rebranded Italian Medical Cannabis Arm as Tilray Medical Italia
• Aurora Cannabis Won EU-wide Protection for its Farm Gas and Sourdough Cannabis Varieties
• Simply Solventless Sharpened Growth Strategy with Uncommon Cannabis Acquisition and Humble Retrofit Progress

Key Takeaways; Psychedelic Sector

• Definium Therapeutics Launched ‘Rerouting Minds’ Campaign to Spotlight the Science Behind Pharmaceutical LSD
• Incannex Healthcare Strengthened its PSX-001 Program with Formation of a High-Profile Clinical Advisory Board

Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.

Top Marijuana Companies for the Week

#1: Tilray

Tilray Medical, which is part of Tilray Brands, Inc. (NASDAQ TLRY) (TSX: TLRY), officially launched Tilray Medical Italia, marking a new phase in its medical cannabis operations in Italy.

The move followed the rebranding of its wholly owned subsidiary, FL Group, which became Tilray Medical Italia on January 1, 2026. The change was publicly announced on January 22 and the company stated that it is part of its wider plan to unify its medical cannabis activities under a single global brand across Europe.

Tilray said Italy is a key regulated market within its European strategy, and by operating under the Tilray Medical Italia name, the company aims to strengthen its local presence while building a more scalable and consistent medical cannabis platform.

“Italy remains a strategically important market for Tilray Medical,” said Rajnish Ohri, President International at Tilray Brands. “The launch of Tilray Medical Italia strengthens our local presence, aligns our operations under a single global medical brand, and reinforces our long-term commitment to supporting patients, physicians, and healthcare systems with high-quality, authorized medical cannabis products.”

Moreover, the company reported that Tilray Medical Italia will work closely with Molteni Farmaceutici, which is an Italian pharmaceutical company with a long-standing presence in hospitals, physician networks, and pharmacies nationwide. According to Tilray, the partnership will focus on physician education, responsible prescribing, and improving patient access to treatment.

“Our collaboration with Molteni allows us to effectively serve the Italian medical community while maintaining the highest standards expected in a regulated pharmaceutical environment,” Ohri added. “As demand continues to evolve, Tilray Medical Italia is well positioned to responsibly support the market’s development.”

Tilray Medical now serves patients in more than 20 countries with established medical cannabis programmes, while working alongside regulators, healthcare professionals, and research partners.

#2: Aurora Cannabis

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) secured European Community Plant Variety Rights for two of its proprietary cannabis strains, Farm Gas and Sourdough, strengthening its intellectual property position across the European Union.

The rights were granted by the EU’s Community Plant Variety Office and provide Aurora with exclusive control over the commercial production, sale, and marketing of the two varieties across all 27 EU member states. The protection lasts between 25 and 30 years and is comparable to a patent for plant genetics.

Aurora stated that the approval builds on existing protections already in place in Canada and other international markets, allowing the company to commercialize its genetics globally while safeguarding long-term investments in research and innovation.

“Being granted Community Plant Variety Rights in the EU is a direct recognition of the exceptional cannabis genetics work underway at our Aurora Coast R&D facility that is unmatched in its level of excellence,” said Lana Culley, Vice President of Innovation and International Operations at Aurora. “This protection not only strengthens Aurora’s global genetics portfolio, but also ensures that our high-quality, differentiated varieties can consistently reach patients and consumers worldwide.”

Both Farm Gas and Sourdough were bred in Canada through Aurora’s in-house breeding and phenotyping programmes. Known internally as SOT20R07-007 and ACB21T044, the cultivars are recognized for their high potency, distinctive aromas, strong bud structure, and reliable performance.

The two strains are already available to medical cannabis patients in several regulated markets, including Germany, Poland, the UK, Canada, and Australia, where Aurora has an established medical presence.

Furthermore, Aurora announced that it had scheduled a conference call to discuss the results for its third quarter 2026 on Wednesday, February 4, 2026, at 8:00 a.m. Eastern Time. Additionally, the Company stated that it will report its financial results for the third quarter of 2026 before the opening of markets that same day.

#3: Simply Solventless

Simply Solventless Concentrates (TSXV: HASH) (OTCPK: SSLCF) outlined a busy start to 2026, announcing the acquisition of cannabis brand Uncommon Cannabis Co. alongside major progress at its Humble Grow Co. cultivation facility and further balance sheet improvements.

On January 22, 2026, the company confirmed it had agreed to acquire Uncommon, which is a dried flower and preroll brand with an established presence in Quebec, Alberta, and Saskatchewan. According to Simply Solventless, the deal gives the company an immediate entry into the dried flower and standard preroll categories, complementing its existing focus on extracts and B2B sales.

“The acquisition of Uncommon is expected to satisfy an important strategic mandate, which is developing adequate markets and sales channels for incremental Humble production, while also providing incremental current cash flow.” said Jeff Swainson, President and CEO of SSC. “We are very encouraged by Uncommon’s potential as we advance through 2026.”

Uncommon generated approximately $1.8 million in gross revenue during 2025 and currently holds around 40 provincial listings across Canada. About 65% of its sales come from Quebec, a market where SSC has limited exposure today.

Under the terms of the transaction, SSC will pay $250,000 in cash over 18 months and issue 750,000 common shares, subject to escrow. The deal also includes approximately $100,000 in net working capital. The acquisition is expected to close following regulatory approvals.

The Uncommon deal aligns with SSC’s preparations for increased cultivation output at its Humble Grow Co. facility in Winnipeg, Manitoba. On January 19, 2026, the company announced that it is completing a retrofit of the former Delta 9 site, which management expects will double production once fully operational.

“All Humble retrofit LED lights have now been ordered, and preliminary schedules suggest 100% retrofit production by early Q3 2026,” Swainson said. “This investment is expected to deliver a payback in under one year.”

According to the company, the retrofit, which includes new LED lighting, irrigation upgrades, dehumidifiers, and airflow improvements, is designed to significantly boost yields without expanding the facility footprint. Once fully ramped up, SSC expects annual gross revenue to rise to between $53.5 million and $65.5 million, with most incremental margin flowing through to EBITDA.

Top Psychedelic Companies for Week

#1: Definium Therapeutics

Definium Therapeutics, Inc. (NASDAQ: DFTX), which was known as Mind Medicine (MindMed) until it recently rebranded to Definium Therapeutics, launched a new educational campaign called “Rerouting Minds.” According to the company, the initiative aims to change how people understand mental health treatment by focusing on the science behind pharmaceutical lysergide (LSD) and its potential role in modern psychiatry.

The company stated that the campaign is designed to open perspectives and provide scientific context at a time when mental health needs are rising and current treatments often fall short. By highlighting ongoing research and historical insights, Definium hopes to foster informed discussion around psychedelics as a new frontier in psychiatry.

“The disconnect between the human impact of psychiatric disorders and the lack of robustly effective and durable options in our treatment toolbox underscores the urgent need for new scientific approaches,” said Dan Karlin, Chief Medical Officer at Definium Therapeutics. He added that rigorous clinical studies investigating psychedelics like LSD are “so important and promising” for addressing psychological distress.

Karlin also emphasized that Definium’s research efforts are part of a broader shift in the field. “Our scientifically rigorous efforts within the psychedelic renaissance are reshaping how we understand LSD’s role in mental health care and as a potential next step in the treatment journey,” he said. According to Karlin, the Rerouting Minds campaign aims to help clinicians and decision-makers better understand the “transformative potential of pharmaceutical LSD” for patients struggling with mental health conditions.

The campaign provides educational resources on the history of LSD, dating back to its synthesis in 1938, as well as current scientific theories on how it may affect the brain. These include hypotheses around serotonin receptor activity and increased neuroplasticity, which could support lasting changes in thought patterns and behavior.

By launching “Rerouting Minds,” Definium hopes to accelerate collaboration and understanding in the evolving field of psychedelic medicine and ultimately help reshape the future of mental health care.

#2: Incannex Healthcare

Incannex Healthcare Inc. (NASDAQ: IXHL) announced the formation of a new Clinical Advisory Board to support the ongoing development of its PSX-001 program for generalized anxiety disorder. The move signals a key step as the clinical-stage biopharmaceutical company advances the treatment into its next phase of development.

According to company, the newly formed board is designed to provide independent clinical and scientific guidance, with a focus on strengthening trial design, regulatory strategy, and long-term development planning for PSX-001. Incannex said that the advisory group will play a central role in ensuring the program remains scientifically rigorous and patient focused.

“The formation of this Clinical Advisory Board represents an important step forward for the PSX-001 program,” said Incannex Healthcare Chief Medical Officer Dr. Lou Barbato. “As we move PSX-001 forward, the collected perspectives of this Clinical Advisory Board will help inform key development decisions and support disciplined execution across clinical and regulatory milestones.”

Barbato added that the board reflects a deliberate and strategic approach to drug development. “This reflects a strategic and intentional approach to drug development, facilitating informed choices that strengthen execution, manage risk, and support long-term shareholder value,” he said.

The inaugural PSX-001 Clinical Advisory Board brings together three internationally respected leaders in psychiatry and neuropsychopharmacology. Each brings decades of research, clinical, and leadership experience in mood and anxiety disorders. They include Dr. C. Neill Epperson, Chair of the Department of Psychiatry at the University of Colorado School of Medicine, Dr. Charles Nemeroff, Chair of Psychiatry and Behavioral Sciences at the University of Texas at Austin’s Dell Medical School, and Dr. Alan Schatzberg, Director of the Stanford Mood Disorders Center.

By assembling a board of this caliber, Incannex aims to reinforce its commitment to evidence-based innovation and disciplined execution as it advances PSX-001, which is an oral synthetic psilocybin treatment being developed for generalized anxiety disorder, toward later-stage clinical development.